Catalyst Biosciences Reports Fourth Quarter and Year-end 2021 Operating & Financial Results and Provides a Corporate Update
March 31, 2022 08:00 ET
|
Catalyst Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., March 31, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced its operating and financial results for the fourth quarter and year ended...
Catalyst Biosciences Regains Rights to CB 2782-PEG for the Treatment of Dry AMD Expands CBIO’s Complement Portfolio in Ophthalmology
March 15, 2022 17:00 ET
|
Catalyst Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., March 15, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced that the company has regained full rights to CB 2782-PEG, a C3-degrader for...
Catalyst Biosciences Engages Perella Weinberg Partners to Assist the Company in Exploring Strategic Alternatives
February 17, 2022 08:00 ET
|
Catalyst Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced it has retained Perella Weinberg Partners (PWP) as a financial advisor to...
Catalyst Biosciences Receives Rare Pediatric Disease Designation for CB 4332 for the Treatment of CFI Deficiency
January 25, 2022 08:00 ET
|
Catalyst Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 25, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric...
Catalyst Biosciences to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference
November 22, 2021 08:00 ET
|
Catalyst Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced that members of its executive management team will participate in a fireside...
Catalyst Biosciences Announces Change in Corporate Strategy
November 12, 2021 07:00 ET
|
Catalyst Biosciences, Inc.
Company to discontinue MarzAA development; focus on developing its complement portfolio Management to host a call today at 8:30 am ET SOUTH SAN FRANCISCO, Calif., Nov. 12, 2021 (GLOBE NEWSWIRE) --...
Catalyst Biosciences Announces CFI Variant Presentations at Two Upcoming Scientific Conferences
October 29, 2021 08:00 ET
|
Catalyst Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Oct. 29, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced that Grant Blouse, Ph.D., chief scientific officer, will present at two...
Catalyst Biosciences Announces Chief Financial Officer Transition
October 13, 2021 16:05 ET
|
Catalyst Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Oct. 13, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced that its chief financial officer, Clinton Musil, has resigned for personal...
FDA Grants Catalyst Biosciences Orphan Drug Designation for MarzAA for the Treatment of Factor VII Deficiency
September 28, 2021 16:01 ET
|
Catalyst Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 28, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug...
Catalyst Biosciences to Present at the Cantor Global Healthcare Conference
September 24, 2021 08:00 ET
|
Catalyst Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 24, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced that a fireside chat including members of its executive management team will...